Could a weekly shot replace daily HIV pills? new trial hints at possibility
NCT ID NCT06061536
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 2 trial tested a new drug called lipovirtide, given as a weekly or biweekly injection, along with daily oral HIV medications. The study enrolled 64 HIV-positive adults who had never taken antiviral drugs before. Researchers measured how many participants had undetectable virus levels after 169 days, aiming to find the best dose and check safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lipovirtide (a weekly or biweekly injection) combined with daily oral nucleoside drugs (3TC and TDF)
What this could lead to
If it works, this could offer a less frequent treatment option for HIV, reducing the burden of daily pills.
What could go wrong
This is a small, early Phase 2 study with only 64 participants. The results may not apply to everyone, and the best dose and safety profile are still being determined.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Second People's Hospital
Tianjin, Tianjin Municipality, 300000, China